Scilex (SCLX) said Wednesday that the US Food and Drug Administration has approved its request for orphan drug designation for colchicine as a treatment for pericarditis.
Gloperba is the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults, the company said.
Shares of Scilex were down more than 11% in recent trading.
Price: 6.14, Change: -0.78, Percent Change: -11.27
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。